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Determining cancer prognosis in patients is crucial to controlling the suffering and death due 
to cancer. In general, the diagnosis of cancer is based on the histology. Histology of cancer is 
determined by the tissue obtained from patients via several sampling approaches, including 
excision or biopsy, fine-needle aspiration, and cytologic smears. As the pathologic diagnosis of 
cancer is an essential initial step for the determination of the line of therapy, pathologists face a 
great responsibility in the diagnosis of cancer. The pathologists evaluate histology for 
characteristics, including nuclear atypia, mitotic activity, cellular density, and tissue 
architecture, incorporating cytologic details and higher-order patterns to classify and grade 
lesions. Therefore, the experience of a pathologist is necessary for accurate diagnosis. 
However, human assessments of histology are problematic, because they are highly subjective. 
Histological grading and staging based on the size of primary tumor, its extent of spread to 
regional lymph nodes, and the presence or absence of metastases are used for predicting a 
biologic behavior of cancer. Prediction of patient outcomes in cancer has been the subject of 
interest to clinicians, healthcare workers and patients. Survival is the most important outcome 
for patients to help them for planning their lives and provide them and their family for caring. 
Traditional methods of outcome prediction in cancer include the Kaplan–Meier non-parametric 
model and the Cox regression semi-parametric model. So far, numerous studies have been 
attempted for predicting the biologic behavior in various types of cancer. Prediction of patient 
outcomes has been applied with several tools including genomic biomarkers, gene expression, 
and epigenetic modifications as well as histology.  
 
In glioma, treatment is dependent on many factors, including patient age and grade. 
However, gliomas assigned to WHO grades III and IV are typically treated very aggressively 
with radiation and concomitant chemotherapy. Histologic diagnosis and grading of gliomas 
have been limited, but the emergence of molecular subtyping has resolved uncertainty related 
to lineage; criteria for grading need to be redefined in the context of molecular subtyping. 
Improving the accuracy and objectivity of grading will directly impact patient care by 
identifying patients who can benefit from more aggressive therapeutic regimens and by 
sparing those with less aggressive disease from unnecessary treatment. Mobadersany et al. 
recently published an elegant study of prediction of cancer outcome by using convolutional 
networks in Proc. Natl. Acad. Sci. USA (Mobadersany et al., 2018). In this study, they show a 
computational approach to predict the overall survival in patients with brain tumors by digital 
pathology images and genomic biomarkers. They examined the ability to predict overall 
survival in diffuse gliomas, a disease with wide variations in outcomes and an ideal test case 
where histologic grading and genomic classifications have independent prognostic power. 
Indeed, artificial intelligence (AI) software learned about survival from histologic images and 
created a unified framework that could integrate histology and genomic biomarkers for 
predicting time-to-event outcomes. Surprisingly, the ability of predicting patient outcomes by 
the AI was ultimately more accurate than that of surgical pathologists. Their study provides 
insights into applications of deep learning in medicine and the integration of histology and 
genomic data and provides methods for dealing with intratumoral heterogeneity and training 
data deficits when using deep learning algorithms to predict survival from histology images.  
 
AI is attracting attention in many fields. Due to the breakthrough of deep learning, it 
rapidly developed in the 2010s. Along with the use of Internet of Things (IoT) and big data, AI 
realized by highly advanced computer processing power and software technology is expected 
to greatly change our lives. Recently, a computer defeated a professional Japanese chess 
(shogi) player for the first time in a public match. Since captured pieces can be used by the 
opposing side, shogi presents a higher degree of complexity than many other strategy games 
and has been of interest to AI researchers. AI has entered the era of full-scale dissemination 
and will change our lives, industries and society including the medical field from now on. 
Recently, technology such as image recognition by deep learning has improved, and it is 
thought that it will bring about a change in the medical field. For detecting tumors, AI will be 
able to detect abnormal values from enormous examination results by X-ray, CT, and MRI as 
well as histopathology. Moreover, if it is done by humans, things that take 10 days can be done 
with AI instantly. Although AI may be responsible for some work, AI is ultimately an auxiliary 
tool to the last, and doctors are still required to be required. Even in the case of predicting a 
patient’s outcome, the doctor's job is to define judgment criteria and make the final judgment 
on whether the results are correct or not. By introducing AI in the pathological field, I believe 
that standard medical treatment will be improved not only in developed countries but also in 
various less developed regions. 
 
In head and neck locale, squamous cell carcinoma is the most common type of cancer. 
Head and neck squamous cell carcinomas (HNSCCs) affect, 600,000 patients per year 
worldwide (Ferlay et al., 2010). Smoking is implicated in the rise of HNSCC in developing 
countries, and the role of human papillomavirus (HPV) is emerging as an important factor in 
the rise of oropharyngeal tumors affecting non-smokers in developed countries (Ang et al., 
2010). Similar to other types of cancer, risk stratification for HNSCC is by anatomic site, stage 
and histological characteristics of the tumor. The prognosis for patients with HPV-positive 
HNSCC is substantially better than that for patients with HPV-negative tobacco-related cancers 
treated similarly (Fakhry et al., 2008). With the recognition of high-risk HPV infection as a risk 
factor for HNSCC and its prognostic importance, HNSCC can be divided for two distinct types, 
HPV-positive and HPV-negative disease. In contrast to HPV-positive HNSCC, HNSCC caused by 
exposure to smoking and alcohol is more likely to be associated with mutations in tumor 
suppressor genes and specifically TP53, making these cancers less sensitive to chemoradiation. 
An inverse correlation between HPV status and TP53 mutation was observed (Westra et al., 
2008). The HPV-positive HNSCCs show unique gene expression and DNA methylation profiles 
(Lechner et al., 2013a). In addition to TP53 mutation, whole-genome sequencing has identified 
additional mutations, such as in the pathways involved in tumor survival (PIK3CA-AKT1-
MTOR-PTEN, EGFR and MET pathways), tumor proliferation (p16, RB, MET, CCND1, 
CDKN2A/CDKN2B), and tumor differentiation (NOTCH1) (Lechner et al., 2013b; Agrawal et al., 
2011). Moreover, the Cancer Genome Atlas Network reported the results of whole-genome 
sequencing on HNSCC (Cancer Genome Atlas Network, 2015). This report shows that HPV-
positive HNSCCs are dominated by helical domain mutations of the oncogene PIK3CA, novel 
alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1 (Cancer 
Genome Atlas Network, 2015). Moreover, smoking-related HNSCCs demonstrate near 
universal loss-of-function TP53 mutations and CDKN2A inactivation with frequent copy 
number alterations including amplification of 3q26/28 and 11q13/22 (Cancer Genome Atlas 
Network, 2015). Recently, single cell analysis of HNSCC including five matched pairs of primary 
tumors and lymph node metastases has revealed that cancer cells varied within and between 
tumors in their expression of signatures related to cell cycle, stress, hypoxia, epithelial 
differentiation, and partial epithelial-to-mesenchymal transition (p-EMT) (Puram et al., 2017). 
Importantly, the p-EMT is an independent predictor of nodal metastasis, grade, and adverse 
pathologic features. Based on these comprehensive analyses, to predict HNSCC patient 
outcomes by using AI, the status of HPV infection, mutation of several genes, and gene 
expression of p-EMT program will be required in addition to histological findings. To apply AI 
in the field of head and neck pathology, the above parameters should be considered for 
predicting patient’s outcome. 
 
In the near future, cancer prediction by using AI will provide an important approach 
to assessing risk and prognosis by identifying individuals at high risk, facilitating the design 
and planning of clinical cancer trials, fostering the development of benefit-risk indices, and 
enabling estimates of the population burden and cost of cancer. It is the task of the pathologist 
to provide an accurate, specific, and sufficiently comprehensive diagnosis to enable the 
clinician to develop an optimal plan of treatment and estimate of prognosis. There are large 
opportunities for more systematic and clinically meaningful data extraction using 
computational approaches. AI may help pathologists to make an accurate diagnosis in the 
combination with molecular pathology to detect the expression of specific genes or gene 
mutations. Diagnosis by pathologists using AI has not yet reached standard practice but may be 
a golden age in the next decade.  
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